GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » Intrinsic Value: Projected FCF

SpectraScience (SpectraScience) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 19, 2024)


View and export this data going back to . Start your Free Trial

What is SpectraScience Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-19), SpectraScience's Intrinsic Value: Projected FCF is $0.00. The stock price of SpectraScience is $1.0E-5. Therefore, SpectraScience's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for SpectraScience's Intrinsic Value: Projected FCF or its related term are showing as below:

SCIE's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.64
* Ranked among companies with meaningful Price-to-Projected-FCF only.

SpectraScience Intrinsic Value: Projected FCF Historical Data

The historical data trend for SpectraScience's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience Intrinsic Value: Projected FCF Chart

SpectraScience Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.08 -0.06 -0.05 -

SpectraScience Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SpectraScience's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, SpectraScience's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpectraScience's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraScience's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where SpectraScience's Price-to-Projected-FCF falls into.



SpectraScience Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get SpectraScience's Free Cash Flow(6 year avg) = $-2.07.

SpectraScience's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep17)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-2.06704+-13.029/0.8)/2928.091
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpectraScience  (GREY:SCIE) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

SpectraScience's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.0E-5/-0.012282814148509
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpectraScience Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of SpectraScience's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraScience (SpectraScience) Business Description

Traded in Other Exchanges
N/A
Address
11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121
SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.
Executives
Lowell Giffhorn officer: CFO 10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines